Opinion Piece Spotlights NICE’s Drug Assessment Methodology in Post-Brexit Britain
March 31, 2020
Lexington Communications Senior Consultant Rebecca Lanning in a recent opinion piece published on Pharmafield looks at NICE’s drug assessment protocol in a post-Brexit Britain.
Lanning says NICE has held a strict assessment methodology, but former British ambassador to Washington Kim Darroch says the U.S. could make an active effort to increase drug prices in an overseas partnership.
“President Trump is said to be actively taking advice on how the NHS can pay more for US medicines and NICE’s price cap – usually beyond the reach of political interference – has been identified as a key target for US negotiators,” Lanning writes.
To read the full article, click here.
